Royalty Pharma (RPRX) Long-Term Debt Repayments (2020)
Royalty Pharma (RPRX) posted Long-Term Debt Repayments of $5.9 billion for Q3 2020, up 15.0% sequentially from $5.2 billion in Q1 2020.
Powered by 
Analysis
Royalty Pharma (RPRX) Long-Term Debt Repayments (2020) Analysis & Trends
Royalty Pharma has reported Long-Term Debt Repayments for 1 years, with the latest figure at $5.9 billion in Q3 2020.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $5.9 billion in Q3 2020, while the trailing twelve-month figure through Jun 2021 was $5.9 billion (up 15.0% YoY) and the FY2020 annual result came in at $11.1 billion, changed N/A from the prior year.
- Long-Term Debt Repayments grew to $5.9 billion in Q3 2020 per RPRX's latest filing, from $5.2 billion in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $5.9 billion in Q3 2020 and troughed at $5.2 billion in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |